AzTrials
AzTrials

BiopsyNCT06541470

Image-Guided Pleural Needle Biopsy in Pleural Diseases

A study testing Cutting needle biopsy and Abrams needle biopsy in people with Biopsy and Diagnosis, run by Eskisehir Osmangazi University at 5 sites in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In recent observational studies show that ultrasound guidance generally increases the success of pleural needle biopsies, it has been shown that the diagnostic success of needle biopsies is compromised and increased when the presence of pleural fluid is associated with a pleural lesion or pleural thickening or pleural… Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Biopsy, Diagnosis, Pleura; Exudate
What is being tested?
Cutting needle biopsy and Abrams needle biopsy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
148 participants
Where
5 sitesTurkey (Türkiye)
Study dates
11 Feb 2021to 2 Jun 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Evidence of exudative pleural effusion for which a specific diagnosis could not be established by clinical, radiological, laboratory, and cytological examination
  • Patients who do not have a high risk of side effects or contraindications for the procedures in question (without bleeding diathesis, who can be positioned appropriately for the biopsy procedure)
  • Willingness to participate in the study
  • Willingness to undergo an invasive procedure
  • Willingness to undergo written consent for randomization and participation in the study.

Who cannot join

  • Presence of parapneumonic effusion
  • Patients with consciousness problems
  • Any contraindication to pleural biopsy (patients with pathology in the chest wall biopsy site (infection) that would preclude biopsy, patients who are taking blood thinners (anticoagulants/antiaggregants) and cannot be interrupted for the procedure to be performed or can be interrupted by bridging with another blood thinner.)
  • Any other systemic disease that could interfere with thoracic computed tomography or ultrasonography assessment.

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

Turkey (Türkiye)5 sites
  • ESOGU Medical Faculty Department of Chest Diseases

    Eskişehir, Meselik - Eskisehir, 26040

  • Muzaffer Metintas

    Eskişehir, Meselik, 26040

  • Selma Metintas

    Eskişehir, Meselik, 26040

  • ESOGU Lung and Pleural Cancers Clinical and Research Center

    Eskişehir, Meselik, 26220

  • Eskisehir Osmangazi University Medical Faculty Department of Chest Diseases

    Eskişehir, Tepebaşı, 260140

Other trials in Turkey (Türkiye)

About this study

Official title: IMAGE-GUIDED PLEURAL NEEDLE BIOPSY IN THE DIAGNOSIS OF PLEURAL DISEASES: ABRAMS NEEDLE OR CUTTING NEEDLE

In recent observational studies show that ultrasound guidance generally increases the success of pleural needle biopsies, it has been shown that the diagnostic success of needle biopsies is compromised and increased when the presence of pleural fluid is associated with a pleural lesion or pleural thickening or pleural nodular lesions. There is no evidence to support a common view on which needle is appropriate in which situation in terms of diagnostic success, reliability of benign diagnoses, and safety of side effects. This study aimed to compare and evaluate the diagnostic yield of the Abrams biopsy needle and the cutting biopsy needle in US-guided pleural needle biopsy to determine which needle is appropriate in which situation. As a result of the study, the diagnostic yield of the cutting needle was found to be higher in cases with pleural thickening of 1 cm or more, and the diagnostic yield of the Abrams needle was found to be higher in patients with pleural thickening of less than 1 cm.

Read the detailed description

AIM A significant proportion of the most common exudative pleural effusions, approximately 40-50%, remain undiagnosed despite repeated thoracentesis and associated diagnostic procedures, including cytology. Histopathological analysis is often required for definitive diagnosis in these patients. For histopathological examination, medical thoracoscopy is generally considered to be the most effective and reliable method of obtaining tissue. However, many studies have shown that image-guided/assisted pleural needle biopsies also have a high diagnostic yield.

In recent years, respiratory physician-guided thoracic ultrasound (TUS) has become increasingly popular due to its contribution to managing pleural disease. TUS successfully guide pleural needle biopsies. Although the observational studies show that ultrasound guidance generally increases the success of needle biopsies, it has been shown that the diagnostic success of needle biopsies is compromised and increased when the presence of pleural fluid is associated with a pleural lesion or pleural thickening or pleural nodular lesions. There is no evidence to support a common view on which needle is appropriate in which situation in terms of diagnostic success, reliability of benign diagnoses, and safety of side effects. This study aimed to compare and evaluate the diagnostic yield of the Abrams biopsy needle and the cutting biopsy needle in US-guided pleural needle biopsy to determine which needle is appropriate in which situation.

METHODS This study was a prospective, randomized, parallel-group study. The Consolidated Standards of Reporting Trials (CONSORT) guidelines were followed for the study protocol. The study was conducted in the Department of Chest Diseases, Faculty of Medicine, Eskisehir Osmangazi University, and Lung and Pleural Cancer Research and Clinical Center from June 2022 to June 2023. The study was approved by the Ethical Committee of Eskisehir Osmangazi University (03.03. 2022/01) and the Ministry of Health ((E-66175679-514.04.01-800014) and was conducted according to the principles of the Declaration of Helsinki. Patients were thoroughly informed before randomization, and their written consent was obtained.

The study included one hundred and seventy-four patients who met the inclusion criteria. Before randomization, all patients underwent contrast-enhanced omputed tomography (CT).

The patients were divided into two groups: The cutting needle group (group A) and the Abrams needle group (group B). Randomization was performed on the subjects enrolled in the study. Block randomization was used with a sequence of 6.

Needle biopsies were performed in the pulmonary endoscopy suite. The biopsy was performed on the endoscopy table. Biopsy was performed using the freehand technique under US guidence. First, the pleural lesion/thickening area the needle could reach was determined as the entry point with the convex probe. The needle entry site was marked on the patient's chest wall immediately before the biopsy. The entry site was then assessed for the safety of the procedure concerning injury to major blood vessels and viscera using the US technique. Tissue sampling was performed according to standard cutting and Abrams needle procedures. After the biopsy procedures, pneumothorax was checked by the US, bleeding complications were checked by Doppler US, and control thoracentesis was performed if necessary.

Patients whose histopathological analyses after needle biopsy did not provide a specific diagnosis and whose diagnosis was reported as fibrinous pleuritis (non-specific pleuritis) were referred for medical or video thoracoscopy, depending on their preference. Patients who has fibrinous pleuritis were followed for at least 12 months. Patients with recurrent symptoms and clinical or radiological signs of disease were re-evaluated during the follow-up period, and invasive diagnostic procedures were repeated as needed. Patients who died or were lost to follow-up during this period were excluded from the analyses.

Histopathological analysis were performed by the same pathologist in the Eskisehir Osmangazi University Medical Faculty Pathology Department with histologic and immonohistochemical investigations.

Statistical analysis:

Study data were recorded in a purpose-designed case report form. A specific database was created, and SPSS version 15.0 (SPSS Inc. Chicago, Illinois) was used for statistical analysis. Patient characteristics were reported as means and percentages using descriptive statistics. The t-test, χ2 test, and two-sided Fisher's exact test were used to compare the groups. The primary endpoint of this study was the determination of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), negative likelihood ratio (LR), and accuracy values with their confidence intervals (CIs) and complication rates of both methods concerning the diagnosis of pleural disease. These values were determined using MedCalc statistical software (version 19.1.16, MedCalc Software Software Ltd, Ostend, Belgium). In the post hoc power analysis, the power of the study was calculated as 95%. ITT (intention-to-treat) analysis was performed to show the effect of dropouts in the randomized groups.

Being tested
Cutting needle biopsy, Abrams needle biopsy
Keywords
Pleura,, Biopsy, Ultrasonography
Medical subject headings
Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cutting needle biopsyProcedure or surgery

    Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.

  • Abrams needle biopsyProcedure or surgery

    Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.

Study groups in NCT06541470
Study groupRoleWhat they receive
Arm A: Cutting needle biopsyOtherPatients with pleural disease underwent US-assisted cutting needle biopsy.
Receives: Procedure: Cutting needle biopsy
Arm B: Abrams needle biopsyOtherPatients with pleural disease underwent US-assisted Abrams needle biopsy.
Receives: Procedure: Abrams needle biopsy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic yield of pleural needle biopsy

    Diagnostic accuracy, sensitiviy and -LR of pleural needle biopsies with cutting or Abrams needle biopsy.

    Measured: 12 months

Secondary outcomes (1)
  1. Safety of pleural needle biopsy

    Determining of the complications for pleural needle biopsies with cutting or Abrams needle biopsy.

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Aug 2024
  2. Study start11 Feb 2021
  3. Primary completion11 Feb 2024
  4. Study completion2 Jun 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective randomized, parallel controlled
Masking
None (open label)
Enrolment
148 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06541470
Sponsor's protocol ID
03.03.2022.01
Status last verified
Aug 2024
First submitted
10 Jul 2024
Last updated
7 Aug 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: INFORMATION ABOUT THE STUDY SUCH AS METHOD, CASES AND RESULTS WILL BE SENT IF REQUESTED.

Questions about this trial

What is this clinical trial studying?

A study testing Cutting needle biopsy and Abrams needle biopsy in people with Biopsy and Diagnosis, run by Eskisehir Osmangazi University at 5 sites in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic yield of pleural needle biopsy (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in